GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

DongKook Life Science Co 303810.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

1,822

-2.04%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About DongKook Life Science Co

Its shares trade on KOSDAQ under the ticker 303810.KQ. It has been listed since 17 February 2025. In the fiscal year to 31 December 2025, it reported revenue of ₩130.34bn and net income of ₩8.66bn. At that date it held total assets of ₩217.63bn and shareholders' equity of ₩131.37bn.

DongKook Life Science Co Ltd is a KR-based company operating in industry. The company is headquartered in Seoul, Seoul. The company went IPO on 2025-02-17. Dongkook Life Science Co Ltd is a Korea-based company principally engaged in the production and sale of contrast agents. The firm is principally engaged in the production and sale of contrast agents such as X-ray contrast agents, magnetic resonance imaging (MRI) contrast agents as well as others. In addition, the Company is engaged in the distribution and sale of medical equipment and medical devices.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
17 Feb 2025
Website
dkls.co.kr ↗

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Seoul, South Korea
  • Engaged in production and sale of contrast agents including X-ray and MRI types
  • Involved in distribution and sale of medical equipment and devices

Weaknesses

  • Sector and industry information not specified
  • IPO date is in the future (2025-02-17)
  • Source description is untrusted and lacks factual verification

Opportunities

  • Potential growth in medical imaging contrast agent market
  • Expansion into distribution of medical equipment and devices
  • Future IPO could attract investment capital

Threats

  • Unclear sector and industry may hinder market positioning
  • Future IPO date may create uncertainty for investors
  • Untrusted source description affects credibility

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.